Patents Represented by Attorney Lucy J. Incyte Pharmaceuticals, Inc. Billings
-
Patent number: 5932443Abstract: The invention provides two human antigens (ANTS) and polynucleotides which identify and encode ANTS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ANTS.Type: GrantFiled: September 26, 1997Date of Patent: August 3, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Olga Bandman, Neil C. Corley, Purvi Shah
-
Patent number: 5932420Abstract: The invention provides a new human integral membrane protein (NIMPH) and polynucleotides which identify and encode NIMPH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NIMPH.Type: GrantFiled: July 14, 1997Date of Patent: August 3, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Purvi Shah
-
Patent number: 5929210Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.Type: GrantFiled: December 23, 1997Date of Patent: July 27, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Susan G. Stuart
-
Patent number: 5925521Abstract: The present invention provides a human serine carboxypeptidase (CPEPT) and polynucleotides which identify and encode CPEPT. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of CPEPT.Type: GrantFiled: March 31, 1997Date of Patent: July 20, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Jennifer L. Hillman, Preeti Lal, Surya K. Goli
-
Patent number: 5925543Abstract: The invention provides a human NADH dehydrogenase B17 subunit (NDB17) and polynucleotides which identify and encode NDB17. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NDB17.Type: GrantFiled: September 12, 1997Date of Patent: July 20, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Y. Tom Tang, Neil C. Corley
-
Patent number: 5922318Abstract: The present invention provides a human ubiquitin conjugation system protein (UCSP) and polynucleotides which encode UCSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of UCSP.Type: GrantFiled: August 13, 1998Date of Patent: July 13, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Neil C. Corley, Preeti Lal, Purvi Shah
-
Patent number: 5922571Abstract: The present invention provides a human protein kinase C inhibitor-like protein (IPKC-2) and polynucleotides which identify and encode IPKC-2. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention provides methods for treating diseases associated with expression of IPKC-2.Type: GrantFiled: March 6, 1997Date of Patent: July 13, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventor: Jennifer L. Hillman
-
Patent number: 5922844Abstract: The present invention provides a polynucleotide (ipka) which identifies and encodes a novel human cAMP-dependent protein kinase A inhibitor homolog (IPKA). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKA. The invention also provides for the use of purified IPKA and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKA. Additionally, the invention provides for the use of antisense molecules to ipka in pharmaceutical compositions for treatment of diseases associated with the expression of IPKA. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipka. The present invention also relates to anti-IPKA antibodies which specifically bind to IPKA.Type: GrantFiled: July 14, 1997Date of Patent: July 13, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Jennifer L. Hillman, Janice Au-Young
-
Patent number: 5919659Abstract: The invention provides a new human phosphatidylinositol transfer protein gamma (PITP.gamma.) and polynucleotides which identify and encode PITP.gamma.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PITP.gamma..Type: GrantFiled: June 11, 1997Date of Patent: July 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5919685Abstract: The invention provides a human aflatoxin B1 aldehyde reductase (AFB1-hAR) and polynucleotides which identify and encode AFB1-hAR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of AFB1-hAR.Type: GrantFiled: August 8, 1997Date of Patent: July 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Purvi Shah, Karl J. Guegler, Neil C. Corley
-
Patent number: 5916749Abstract: The present invention provides a novel human phosphatase inhibitor protein (HPIP) and polynucleotides which identify and encode HPIP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPIP and a method for producing HPIP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPIP, and their use, in the prevention and treatment of diseases associated with expression of HPIP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPIP for the treatment of diseases associated with the expression of HPIP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPIP.Type: GrantFiled: December 13, 1996Date of Patent: June 29, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5917028Abstract: The present invention provides a novel human phosphoprotein (hPSHP) and polynucleotides which identify and encode hPSHP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding hPSHP. The invention also provides pharmaceutical compositions containing hPSHP or agonists and antagonists to hPSHP, and in the use of these compositions for the treatment of diseases associated with hPSHP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding hPSHP for the treatment of diseases associated with the expression of hPSHP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding hPSHP or anti hPSHP antibodies which specifically bind to hPSHP.Type: GrantFiled: October 29, 1996Date of Patent: June 29, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventor: Jennifer L. Hillman
-
Patent number: 5916764Abstract: The present invention provides a human phosphatidylinositol synthase (PISH) and polynucleotides which identify and encode PISH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PISH and a method for producing PISH. The invention also provides for agonists, antibodies, or antagonists specifically binding PISH, and their use, in the prevention and treatment of diseases associated with expression of PISH. The invention also provides for the use of PISH in screening for antiprotozoal and antifungal therapeutics. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding PISH for the treatment of diseases associated with the expression of PISH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding PISH.Type: GrantFiled: December 10, 1996Date of Patent: June 29, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5912143Abstract: The present invention provides a human MAGE-like protein (MAGELP) and polynucleotides which identify and encode MAGELP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding MAGELP and a method for producing MAGELP. The invention also provides for agonists, antibodies, or antagonists specifically binding MAGELP, and their use, in the prevention and treatment of diseases associated with expression of MAGELP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding MAGELP for the treatment of diseases associated with the expression of MAGELP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding MAGELP.Type: GrantFiled: December 27, 1996Date of Patent: June 15, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5906923Abstract: The invention provides a novel human ATPase inhibitor protein (HATPI) and polynucleotides which identify and encode HATPI. The invention also provides genetically engineered expression vectors and host cells containing the nucleic acid sequences encoding HATPI. The invention also provides pharmaceutical compositions containing HATPI or antagonists to HATPI, and in the use of these compositions for the treatment of diseases associated with the expression of HATPI. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HATPI for the treatment of diseases associated with the expression of HATPI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HATPI or anti-HATPI antibodies which specifically bind to HATPI.Type: GrantFiled: July 15, 1997Date of Patent: May 25, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventor: Jennifer L. Hillman
-
Patent number: 5891674Abstract: The invention provides a human insulin receptor tyrosine kinase substrate (IRS-p53h) and polynucleotides which identify and encode IRS-p53h. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IRS-p53h.Type: GrantFiled: June 19, 1997Date of Patent: April 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Purvi Shah
-
Patent number: 5892015Abstract: The present invention provides a human rhombotin-like protein (RBTNH) and polynucleotides which identify and encode RBTNH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding RBTNH and a method for producing RBTNH. The invention also provides for agonists, antibodies, or antagonists specifically binding RBTNH, and their use, in the prevention and treatment of diseases associated with expression of RBTNH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding RBTNH for the treatment of diseases associated with the expression of RBTNH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding RBTNH.Type: GrantFiled: December 27, 1996Date of Patent: April 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventor: Jennifer L. Hillman
-
Patent number: 5889170Abstract: The present invention provides a novel human integral membrane (IMP-2) and polynucleotides which identify and encode IMP-2. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding IMP-2 and a method for producing IMP-2. The invention also provides for agonists, antibodies, or antagonists specifically binding IMP-2, and their use, in the prevention and treatment of diseases associated with expression of IMP-2. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding IMP-2 for the treatment of diseases associated with the expression of IMP-2. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding IMP-2.Type: GrantFiled: January 31, 1997Date of Patent: March 30, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5885803Abstract: The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.Type: GrantFiled: June 19, 1997Date of Patent: March 23, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Surya K. Goli, Purvi Shah
-
Patent number: 5882890Abstract: The present invention provides two regulators of G-protein signaling (designated individually as RGPS-1 and RGPS-2, and collectively as RGPS) and polynucleotides which identify and encode RGPS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention also provides methods for producing RGPS and for treating or preventing disorders associated with expression of RGPS.Type: GrantFiled: March 31, 1997Date of Patent: March 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli